Resistance to mTOR inhibitor in metastatic dialysis-related renal cell carcinoma
| Project/Area Number |
24592410
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OYA Mototsugu 慶應義塾大学, 医学部, 教授 (00213885)
ASANUMA Hiroshi 慶應義塾大学, 医学部, 講師 (70245570)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 透析腎癌 / mTOR / 腎細胞癌 / 分子標的治療 / mTOR阻害薬 |
|---|
| Outline of Final Research Achievements |
In dialysis-related renal cell carcinoma, mTOR was more strongly activated compared with conventional renal cell carcinoma. In addition, constitutive activation was also found in renal tubular cell in dialysis kidney, which would affect dialysis-related cancer initiation. Tyrosine kinase inhibitors accelerated mTOR activation in dialysis-related renal cell carcinoma.
|
Report
(4 results)
Research Products
(4 results)
